Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
DOI: https://doi.org/10.2147/PPA.S401480
2023-04-18
Patient Preference and Adherence
Abstract:Nicole M Engel-Nitz, 1 Mary G Johnson, 1 Michael P Johnson, 1 Ashley S Cha-Silva, 2 Samantha K Kurosky, 2 Xianchen Liu 2 1 Optum, Eden Prairie, MN, 55344, USA; 2 Pfizer Inc, New York, NY, 10017, USA Correspondence: Nicole M Engel-Nitz, HEOR | Optum Life Sciences, MN950-1000, 11000 Optum Circle, Eden Prairie, MN, 55344, USA, Tel +1 952-205-7770, Email Purpose: To assess adherence and persistence with palbociclib therapy in patients with HR+/HER2- metastatic breast cancer (mBC) in a US real-world setting. Methods: This retrospective study evaluated palbociclib dosing, adherence, and persistence using commercial and Medicare Advantage with Part D claims data from the Optum Research Database. Adult patients with mBC who had continuous enrollment 12 months prior to mBC diagnosis and initiated first-line palbociclib with aromatase inhibitor (AI) or fulvestrant between 02/03/2015 and 12/31/2019 were included. Demographic and clinical characteristics, palbociclib dosing and dose changes, adherence (medication possession ratio [MPR]), and persistence were measured. Adjusted logistic and Cox regression models were used to examine demographic and clinical factors associated with adherence and discontinuation. Results: Patients (n = 1066) with a mean age of 66 years were included; 76.1% received first-line palbociclib+AI and 23.9% palbociclib+fulvestrant. Most patients (85.7%) initiated palbociclib at 125 mg/day. Of the 34.0% of patients with a dose reduction, 82.6% reduced from 125 to 100 mg/day. Overall, 80.0% of patients were adherent (MPR), and 38.3% discontinued palbociclib during a mean (SD) follow-up of 16.0 (11.2) and 17.4 (13.4) months, for palbociclib+fulvestrant and palbociclib+AI, respectively. Annual income below &dollar75,000 was significantly associated with poor adherence. Older age (age 65– 74 years (hazard ratio [HR] 1.57, 95% CI, 1.06, 2.33), age ≥ 75 years (HR 1.61, 95% CI: 1.08, 2.41)) and bone-only metastatic disease (HR 1.37, 95% CI, 1.06, 1.76) were significantly associated with palbociclib discontinuation. Conclusion: In this real-world study, > 85% of patients started palbociclib at 125 mg/day and 1 in 3 had dose reductions during the follow-up. Patients were generally adherent and persistent with palbociclib. Older age, bone-only disease, and low-income levels were associated with early discontinuation or non-adherence. Further studies are needed to understand the associations of clinical and economic outcomes with palbociclib adherence and persistence. Keywords: breast cancer, palbociclib, adherence, persistence, metastatic Breast cancer is the most frequent cancer among women. The treatment goal of metastatic breast cancer (mBC) is extending patient survival time while sustaining quality of life. Endocrine therapy (aromatase inhibitor [AI] or fulvestrant) in combination with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is recommended as first-line treatment for patients with hormone-receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) mBC. Treatment adherence is crucial for meeting treatment goals. This observational study sought to evaluate adherence and persistence with palbociclib therapy in patients with HR+/HER2- mBC identified among commercial and Medicare Advantage with Part D enrollees in the Optum Research Database between 02/03/2015 and 12/31/2019. Overall, 1066 patients, with average age around 66 years were assessed; 73.6% were post-menopausal; 76.1% were treated with first-line palbociclib combined with aromatase inhibitors and 23.9% palbociclib combined with fulvestrant. Most patients (85.7%) started palbociclib at the dose of 125 mg/day. About one-third of the patients reduced their dose strength, and most of the patients who reduced strength (83%) reduced to 100 mg/day. Overall, 80.0% of patients were adherent to treatment, and just under 40% discontinued palbociclib during average follow-up periods of 16.0 and 17.4 months, for palbociclib+fulvestrant and palbociclib+AI, respectively. Patients with income below $75,000/year were one-third less likely to be adherent. Also, age ≥65 years and bone-only metastatic disease were significantly associated with discontinuing palbociclib. More studies are needed for supportive evidence. Breast cancer, the most common cancer in women in the United States (US), was newly diagnosed in an estimated 280,000 women in 2021. 1 Six percent of new breast cancer cases present with distant metastases, for which the 5-year relative survival rate is 29%. 1 The intent of metastatic breast cancer (mBC) treatment is to extend survival while maintaining quality of life. 2 Molecular subtype, defined by hormone receptor -Abstract Truncated-
medicine, general & internal